Skip to content

A Clinical Study on the Efficacy of Wanxin A.M.L. Lenses in Controlling Myopic Progression in Children

A Clinical Study on the Efficacy of Wanxin A.M.L. Lenses in Controlling Myopic Progression in Children

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116791
Enrollment
Unknown
Registered
2026-01-15
Start date
2026-03-22
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Intervention Group:Wear the A.M.L. spectacles during all waking hours.

Sponsors

Shanghai Eye Disease Prevention and TreatmentCenter
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Accompanied by a parent or legal guardian capable of reading and understanding Chinese/English, who provides written informed consent/assent. 2.Capable of understanding and participating in the consent/assent procedure. 3.Aged 6 to 12 years (inclusive) at the time of enrollment. 4.Diagnosed with myopia, with a cycloplegic objective spherical equivalent refractive error between -0.50D and -5.00D. 5.Absolute value of astigmatism = 0.8 (Snellen equivalent) in each eye. 8.Normal ocular examination findings. 9.Willingness to comply with the investigator's instructions regarding the trial lenses and to attend all scheduled follow-up visits.

Exclusion criteria

Exclusion criteria: 1.Known systemic or ocular diseases that may affect vision or refraction (including infections). 2. Systemic diseases affecting ocular health (e.g., diabetes mellitus, Graves' disease, ankylosing spondylitis, multiple sclerosis, Sjögren's syndrome, systemic lupus erythematosus). 3.Use of systemic or topical medications known to alter ocular status/affect ocular health during the study period. 4.History of ocular trauma. 5.Amblyopia. 6.Manifest strabismus. 7. Use of myopia control interventions (e.g., orthokeratology lenses, atropine) within 1 month prior to enrollment. 8.History of ocular surgery. 9.Known allergy to any component of cycloplegic eye drops. 10.Concurrent participation in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
Change in cycloplegic spherical equivalent refraction>= 0.75 D per year;

Secondary

MeasureTime frame
Axial elongation >= 0.20 mm per year;vision;Subjective experience and compliance with spectacle wear;

Countries

China

Contacts

Public ContactXiangui He

Shanghai Eye Disease Prevention and TreatmentCenter

xianhezi@163.com+86 21 5355 5032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026